Kevin R. Lynch
Founder at SphynKx Therapeutics LLC
Profile
Kevin R.
Lynch founded SphynKx Therapeutics LLC in 2010, where he is working as Chief Scientific Officer from 2010.
Dr. Lynch also founded Catena Pharmaceuticals, Inc., where he worked as Vice President-Biological Sciences from 2010 to 2013.
Dr. Lynch also currently works at The University of Virginia School of Medicine, as Vice Chairman and the University of Virginia, as Professor-Pharmacology & Biochemistry from 2012.
Dr. Lynch received his doctorate degree in 1980 from the University of Rhode Island.
Kevin R. Lynch active positions
| Companies | Position | Start |
|---|---|---|
| University of Virginia | Corporate Officer/Principal | - |
SphynKx Therapeutics LLC
 SphynKx Therapeutics LLC Pharmaceuticals: MajorHealth Technology SphynKx Therapeutics LLC engages in developing, discovering and commercializing novel therapies for the treatment of fibrosis. Its Sphingosine 1-phosphate (S1P) is recognized as a key regulator of many of the cellular processes that promote wound healing and fibrogenesis, which include fibroblast and immune cell migration, vascular leak, proliferation, angiogenesis, and TGF-ß signaling. The company was founded by Andrew Bolt, Kevin R. Lynch, Webster Santos and Timothy L. Macdonald in 2010 and is headquartered in Charlottesville, VA. | Founder | 2009-12-31 |
| The University of Virginia School of Medicine | Director/Board Member | - |
Former positions of Kevin R. Lynch
| Companies | Position | End |
|---|---|---|
Catena Pharmaceuticals, Inc.
 Catena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Catena Pharmaceuticals, Inc. is focused on the development and commercialization of novel GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's proprietary chemistry is uniquely capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states. Catena focuses its research and product development efforts around manipulation of the biology of the blood-borne signaling molecule lysophosphatidic acid (LPA). Its products will either block the signaling of LPA, or reduce production of LPA, or mimic LPA. The company was founded by Kevin Lynch and Tim MacDonald in the year 2008 and is headquartered in Durham, NC. | Founder | 2013-07-08 |
Training of Kevin R. Lynch
| University of Rhode Island | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Catena Pharmaceuticals, Inc.
Catena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Catena Pharmaceuticals, Inc. is focused on the development and commercialization of novel GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's proprietary chemistry is uniquely capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states. Catena focuses its research and product development efforts around manipulation of the biology of the blood-borne signaling molecule lysophosphatidic acid (LPA). Its products will either block the signaling of LPA, or reduce production of LPA, or mimic LPA. The company was founded by Kevin Lynch and Tim MacDonald in the year 2008 and is headquartered in Durham, NC. | Health Technology |
SphynKx Therapeutics LLC
SphynKx Therapeutics LLC Pharmaceuticals: MajorHealth Technology SphynKx Therapeutics LLC engages in developing, discovering and commercializing novel therapies for the treatment of fibrosis. Its Sphingosine 1-phosphate (S1P) is recognized as a key regulator of many of the cellular processes that promote wound healing and fibrogenesis, which include fibroblast and immune cell migration, vascular leak, proliferation, angiogenesis, and TGF-ß signaling. The company was founded by Andrew Bolt, Kevin R. Lynch, Webster Santos and Timothy L. Macdonald in 2010 and is headquartered in Charlottesville, VA. | Health Technology |
- Stock Market
- Insiders
- Kevin R. Lynch
